We have amazing news today as the first CE mark for next generation sequencing-based molecular diagnostics was just announced. Illumina applied CE mark to MiSeqDx™ Cystic Fibrosis System and Omixon Target is used for analyzing CFTR gene in prenatal labs!

An excerpt from the announcement relevant to Omixon Target:

Cystic fibrosis is a life-threatening, inherited single-gene disorder that affects more than 70,000 people worldwide. Caused by mutations in the CFTR gene, the disease has a wide clinical presentation depending on which CFTR gene mutations are present. Most CFTR mutations are rare, and their distribution and frequency vary among different world populations.